296 related articles for article (PubMed ID: 25444984)
1. 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.
Pascal LE; Masoodi KZ; O'Malley KJ; Shevrin D; Gingrich JR; Parikh RA; Wang Z
J Urol; 2015 Apr; 193(4):1388-93. PubMed ID: 25444984
[TBL] [Abstract][Full Text] [Related]
2. 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.
Masoodi KZ; Ramos Garcia R; Pascal LE; Wang Y; Ma HM; O'Malley K; Eisermann K; Shevrin DH; Nguyen HM; Vessella RL; Nelson JB; Parikh RA; Wang Z
Endocrinology; 2013 Jul; 154(7):2296-307. PubMed ID: 23671262
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
Gupta S; Wang Y; Ramos-Garcia R; Shevrin D; Nelson JB; Wang Z
Prostate; 2010 Oct; 70(14):1575-85. PubMed ID: 20564326
[TBL] [Abstract][Full Text] [Related]
4. Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model.
Wang Y; Gupta S; Hua V; Ramos-Garcia R; Shevrin D; Jovanovic BD; Nelson JB; Wang Z
Prostate; 2010 Feb; 70(2):147-54. PubMed ID: 19739129
[TBL] [Abstract][Full Text] [Related]
5. Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.
Garcia RR; Masoodi KZ; Pascal LE; Nelson JB; Wang Z
Am J Clin Exp Urol; 2014; 2(1):82-91. PubMed ID: 25374909
[TBL] [Abstract][Full Text] [Related]
6. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
Li Z; Alyamani M; Li J; Rogacki K; Abazeed M; Upadhyay SK; Balk SP; Taplin ME; Auchus RJ; Sharifi N
Nature; 2016 May; 533(7604):547-51. PubMed ID: 27225130
[TBL] [Abstract][Full Text] [Related]
7. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
Azzouni F; Mohler J
Urology; 2012 Jun; 79(6):1197-205. PubMed ID: 22446342
[TBL] [Abstract][Full Text] [Related]
8. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.
Tunn UW; Canepa G; Kochanowsky A; Kienle E
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):296-302. PubMed ID: 22733160
[TBL] [Abstract][Full Text] [Related]
9. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
10. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
[TBL] [Abstract][Full Text] [Related]
11. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model.
Eggener SE; Stern JA; Jain PM; Oram S; Ai J; Cai X; Roehl KA; Wang Z
Prostate; 2006 Apr; 66(5):495-502. PubMed ID: 16372330
[TBL] [Abstract][Full Text] [Related]
14. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
15. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
16. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
J Urol; 2012 Jun; 187(6):2074-81. PubMed ID: 22498230
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
Bruchovsky N; Klotz LH; Sadar M; Crook JM; Hoffart D; Godwin L; Warkentin M; Gleave ME; Goldenberg SL
Mol Urol; 2000; 4(3):191-9;discussion 201. PubMed ID: 11062374
[TBL] [Abstract][Full Text] [Related]
18. Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation.
Hamid AR; Verhaegh GW; Smit FP; van Rijt-van de Westerlo C; Armandari I; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
J Urol; 2015 Mar; 193(3):1023-9. PubMed ID: 25242390
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.
Nnane IP; Long BJ; Ling YZ; Grigoryev DN; Brodie AM
Br J Cancer; 2000 Jul; 83(1):74-82. PubMed ID: 10883671
[TBL] [Abstract][Full Text] [Related]
20. Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor.
Shiota M; Kiyoshima K; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Takahashi R; Inokuchi J; Tatsugami K; Eto M
J Urol; 2017 Feb; 197(2):308-313. PubMed ID: 27506696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]